SCHEMBL17754508

SCHEMBL17754508

B[C@@H]1O[C@H](COC)C(OP(=O)(S)CC)[C@@H]1OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17754502 0.88 — —
SCHEMBL17754512 0.87 — —
SCHEMBL17754490 0.87 — —
SCHEMBL19566535 0.87 — —
SCHEMBL20334497 0.87 — —
SCHEMBL24778340 0.85 — —
SCHEMBL21202663 0.85 — —
SCHEMBL15964498 0.85 — —
SCHEMBL17754493 0.84 — —
SCHEMBL17754513 0.84 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170319614-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2017-11-09 — — US disclosed
US-20170319614-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2017-11-09 — — US disclosed
US-20160138029-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2016-05-19 — — US disclosed
US-20160138029-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2016-05-19 — — US disclosed
Send feedback